Spyglass

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on: 
Tuesday, April 2, 2024
IOP, Bimatoprost, Glaucoma, Ocular hypertension, Pressure, IOL, ASCRS, Patient, Tissue, Cataract, Month, Spyglass, Visual acuity, Society, Safety, IOPS, Therapy, FDA, Intraocular pressure, Annual general meeting, Pharmaceutical industry

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points: 
  • ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
  • The SpyGlass platform was well tolerated and there were no adverse events related to the product.
  • These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
    “SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
  • The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.

SpyGlass Pharma Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform

Retrieved on: 
Tuesday, December 5, 2023
IOP, Cataract, Entrepreneurship, Food, FDA, MBA, Health, Intraocular pressure, Ocular hypertension, Ophthalmology, Device, Growth, Patient, Safety, Ahmad, KDB, Spyglass, Glaucoma, Management

Dr. Goodkin and Mr. Khan each bring a wealth of experience to support the growth and continued development of the SpyGlass intraocular drug delivery platform.

Key Points: 
  • Dr. Goodkin and Mr. Khan each bring a wealth of experience to support the growth and continued development of the SpyGlass intraocular drug delivery platform.
  • Goodkin’s deep expertise in ophthalmic clinical development and regulatory proceedings make her uniquely qualified to lead our clinical program,” said Patrick Mooney, CEO of SpyGlass Pharma™.
  • Goodkin’s extensive leadership experience and personal conviction to improve patient care will enhance this company’s dedicated leadership team.
  • SpyGlass recently initiated a Phase I/II study to investigate the safety and efficacy of its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.

SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform

Retrieved on: 
Tuesday, October 31, 2023
FDA, Intraocular pressure, Ocular hypertension, Glaucoma, IOP, Entrepreneurship, Phase, Clinical trial, Bimatoprost, Safety, Patient, Cataract, Spyglass, Pharmaceutical industry, Medical device, IOL

ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.

Key Points: 
  • ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.
  • The SpyGlass platform is designed to be implanted at the time of routine cataract surgery and deliver multiple years of bimatoprost, to lower intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
  • “The initiation of our Phase I/II study is an exciting and significant milestone for the company,” said Malik Y. Kahook, M.D., Co-Founder, Executive Chair and President of SpyGlass Pharma™.
  • “We are enthusiastic about conducting this vital research and working with the FDA to advance our platform through clinical development,” said Patrick Mooney, CEO of SpyGlass Pharma™.

Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 13, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Neoplasm, RNR, Biology, AACR, Deoxyribonucleotide, DNA, A-DNA, Bio, IND, Survival, CRC, Boundless, Patient, Preclinical imaging, Growth, Colorectal cancer, Drug discovery, MAPK, Conference, Investigational New Drug, HSR, Spyglass, Medical imaging, Pharmaceutical industry, Cytidine monophosphate

BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.

Key Points: 
  • BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.
  • BBI-825 has demonstrated RNR inhibition in a host of tumor cell lines and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being evaluated in Investigational New Drug (IND)-enabling studies.
  • BBI-825 was discovered using Boundless Bio’s proprietary Spyglass platform, a drug discovery engine to identify and preclinically validate targets that are essential for cancer cells’ reliance on ecDNA for growth, treatment resistance, and survival.
  • Details of today’s presentations are as follows:
    Title: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRASG12C inhibitor in colorectal cancer (CRC)

Naval Maritime Autonomy Company Raises $55 Million in Series A Fundraise

Retrieved on: 
Tuesday, October 10, 2023
Multimedia, Navy, Lightspeed Venture Partners, Ecosystem, Growth, Saronic Gulf, Cutlass, Software, Research, Spyglass, Shipbuilding

AUSTIN, Texas, Oct. 10, 2023 /PRNewswire/ -- Saronic , a maritime autonomy company focused on surface vessels, announced today a $55 million Series A funding round led by Caffeinated Capital, with participation from 8VC, U.S.

Key Points: 
  • AUSTIN, Texas, Oct. 10, 2023 /PRNewswire/ -- Saronic , a maritime autonomy company focused on surface vessels, announced today a $55 million Series A funding round led by Caffeinated Capital, with participation from 8VC, U.S.
  • "We have been astounded by the speed at which this exceptional team has already begun to bridge the technology gap in naval autonomy."
  • These systems enable real-time, collaborative, and autonomous mission-level decision-making, and are designed to navigate the challenges of maritime environments.
  • This investment reflects a strong belief in the team's capability to rapidly provide autonomous solutions tailored to the modern naval landscape.

Swirl Metasearch Version 2.0 Now Available with Connectors for Microsoft 365 Apps

Retrieved on: 
Thursday, June 15, 2023
Transfer, SharePoint, Elastic, PostgreSQL, OpenSearch, Microsoft, Multimedia, Apache, Spyglass, OneDrive, BigQuery, Metasearch engine, ServiceNow, API, JetBrains, Online shopping, Swirl, Apache Solr, Atlassian

WALTHAM, Mass., June 15, 2023 /PRNewswire/ -- Swirl, the company behind the open-source Swirl Metasearch engine, today announced general availability of version 2.0, featuring enterprise-grade OAUTH2 support and pre-configured connectors to Microsoft 365 Outlook, OneDrive, Teams and SharePoint.

Key Points: 
  • WALTHAM, Mass., June 15, 2023 /PRNewswire/ -- Swirl, the company behind the open-source Swirl Metasearch engine, today announced general availability of version 2.0, featuring enterprise-grade OAUTH2 support and pre-configured connectors to Microsoft 365 Outlook, OneDrive, Teams and SharePoint.
  • Swirl, the company behind the Swirl Metasearch engine, announced version 2.0 featuring Microsoft 365 integration.
  • "Swirl Metasearch solves cross-silo enterprise search problems without the massive time and effort required to copy and index data.
  • Swirl Metasearch is now available as a managed service.

Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, DNA, CRISPR, AACR, Therapy, Bio, Neoplasm, Clinical trial, American Association for Cancer Research, Research, Spyglass, A-DNA, Genome, Oncogene, Patient, Cancer, FDA, Vaccine, Pharmaceutical industry

Boundless Bio , a clinical stage next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023.

Key Points: 
  • Boundless Bio , a clinical stage next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023.
  • The poster “ Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition ” is available for in-person presentation on April 17, 2023 at 9:00 a.m. - 12:30 p.m.
  • "We are excited to unveil CHK1 as the ecDNA-essential target for our first novel ecDNA-directed therapy (ecDTx),” said Christian Hassig, Ph.D., Chief Scientific Officer of Boundless Bio.
  • We designed BBI-355, an orally available, highly potent, and selective inhibitor of CHK1 to target this unique genetic susceptibility in ecDNA-bearing cancer cells.

Espolòn® Tequila Proves It's So Smooth You'll Scream, As The Official Tequila Partner of the Year's Most Anticipated Horror Movie, Scream VI

Retrieved on: 
Thursday, February 16, 2023
Campari America, Espresso martini, Running, Scream, Woodsboro, Agave, The White Spirit, Tequila, Drizly, Spyglass Media Group, Spyglass, Paramount Pictures, Partnership, Scream VI, Citrus, Social media, Ghostface, Entertainment, Film industry

NEW YORK, Feb. 16, 2023 /PRNewswire/ -- Espolòn® Tequila announced today that the brand will be the official tequila partner of one of this year's most anticipated films, Scream VI, through an exclusive collaboration with Paramount Pictures and Spyglass Media Group.

Key Points: 
  • Witness the horror in theatres on March 10th and see why Espolòn is the tequila so smooth, you'll scream.
  • Fans at home can also mix up the official cocktail of Scream VI, Espolòn's Empire Screamer, in preparation for the film to hit theatres.
  • "Scream has been changing the game in horror for decades past and present, captivating audiences with each movie and always remaining timely and relevant in pop culture.
  • For more information on Espolòn Tequila's Scream VI partnership, please visit espolontequila.com or follow on Instagram @ espolontequila .

North Coast Brewing's Immersive Tasting Experience in Virtual Reality

Retrieved on: 
Thursday, February 9, 2023
Carbon, State, High production volume chemicals, North Coast Brewing Company, Pleasure, Golden, Carbon farming, Stout, Spyglass, Beauty, Recreation, Education, Virtual reality, NCBC, Meta, Beer, Amusement park, Tourism

FORT BRAGG, Calif., Feb. 8, 2023 /PRNewswire/ -- North Coast Brewing Company (NCBC) announced its latest offering, a virtual craft beer tasting experience.

Key Points: 
  • FORT BRAGG, Calif., Feb. 8, 2023 /PRNewswire/ -- North Coast Brewing Company (NCBC) announced its latest offering, a virtual craft beer tasting experience.
  • NCBC has partnered with Spyglass to develop and distribute an exclusive virtual beer tasting experience with connoisseurs throughout California.
  • They will also experience a virtual visit to Fortunate Farm, NCBC's longtime partner in a Carbon Farming project.
  • Spyglass builds experience platforms to deliver high-production, high-quality immersive experiences for recreation, entertainment, and education through virtual reality.

SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

Retrieved on: 
Friday, February 3, 2023
Food, MD, Ocular hypertension, IND, Cataract, Entrepreneurship, Spyglass, Animation, University of Colorado School of Medicine, Glaucoma, Drug discovery, Intraocular pressure, New Enterprise Associates, IOP, Patient, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Sue, Bimatoprost, Intraocular lens, University, Pharmaceutical industry, IOL, Medicine

“We’ve known for decades that patient adherence to daily drop regimens is an impediment to treating ophthalmic diseases.

Key Points: 
  • “We’ve known for decades that patient adherence to daily drop regimens is an impediment to treating ophthalmic diseases.
  • These data give a clear signal that the SpyGlass drug delivery system is a breakthrough platform technology with real potential to disrupt the way our most effective therapies are administered long-term.
  • The SpyGlass drug delivery platform with bimatoprost is designed to enable every cataract surgeon the ability to provide unprecedented, multi-year glaucoma therapy at the time of routine cataract surgery.
  • The SpyGlass team is busily preparing our Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA).